Evidence-Based Strategies for Selecting and Sequencing Systemic Therapies in RCC: Highlights From ASCO GU 2022 and Beyond

Tian Zhang, MD, provides an overview of renal cell carcinoma (RCC).

Mehmet A. Bilen, MD, discusses the CLEAR trial that looked at lenvatinib with pembrolizumab as first-line therapy for RCC.

Pedro C. Barata, MD, MSc, reviews the data from the KEYNOTE-426 trial, which focused on axitinib with pembrolizumab.

Moshe C. Ornstein, MD, MA, explains the results from the CheckMate 9ER trial that studied cabozantinib with nivolumab.

David Braun, MD, delves into data from the CheckMate 214 trial that focused on ipilimumab with nivolumab.

Dr Bilen discusses factors to consider when choosing a first-line therapy for advanced clear-cell RCC

7.Dr Ornstein explains how he selects between IO-TKI and IO-IO therapy in the first-line setting in advanced RCC.

Drs Barata and Ornstein describe how they treat certain subgroups of patients with advanced RCC, particularly those with brain or bone metastases.

Dr Braun explains how biomarkers help to stratify treatment decision-making for patients with RCC.

Dr Ornstein weighs in on interpreting quality of life data from important RCC trials to help with treatment decision-making.

The panel elaborates on novel agents and combination treatments that are currently being evaluated for the first-line setting in advanced RCC.

Mehmet A. Bilen, MD, explains how triplet regiments might impact treatment selection for first line and beyond.

Dr Zhang discusses recently approved adjuvant systemic therapy for patients with RCC who have a high risk of recurrence after nephrectomy.

David Braun, MD, touches on how the choice of adjuvant therapy can impact subsequent treatment selection in advanced RCC.

Dr Bilen reviews some ongoing trials looking into monotherapy and combination therapies in the adjuvant setting in RCC.

Pedro Barata, MD, MSc, provides a brief overview of ongoing trials in the neoadjuvant setting in patients with RCC.

Dr Ornstein describes how the choice of neoadjuvant therapy can impact subsequent treatment selection in advanced RCC.

Drs Zhang and Ornstein discuss regimens for advanced clear-cell RCC in the second-line setting and beyond, focusing on the METEOR, CABOSEQ,TIVO-3 CHeckMate 025, and AXIS trials.

Dr Barata comments on sequencing therapies in the second line and beyond in patients with advanced RCC.

Dr Bilen discusses the potential use of cabozantinib as a first-line therapy in patients who receive immunotherapy in the adjuvant setting.

The panel concludes with final thoughts on unmet needs and future perspectives for the treatment of advanced clear-cell RCC.